ImmuCell Corporation (ICCC)

ImmuCell Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-0.55	-1.04	-2.16	-5.77	-2.49	-0.08
Depreciation & Amortization	2.58	2.73	2.69	2.72	2.49	2.46
Stock-Based Compensation	0.38	0.3	0.33	0.37	0.27	0.14
Other Adjustments	-0.08	2.54	-0.09	0.13	0.03	0.05
Change in Receivables	0.65	0.35	-1.59	-0.43	0.94	-0.9
Changes in Inventories	-1.32	-2.15	0.7	-1.77	-2.95	-1
Changes in Accounts Payable	0.19	-0.2	0.36	0.16	0.34	0.25
Changes in Other Operating Activities	-0.05	-0.06	0.12	-0.07	-0.16	0.03
Operating Cash Flow	4.47	2.48	0.36	-4.67	-1.54	0.95
Operating Cash Flow Growth	195.69%	591.61%	-	-	-	-27.47%
Capital Expenditures	-1.1	-1.25	-0.47	-1.89	-3.98	-2.61
Sale of Property, Plant & Equipment	0.05	0.04	0	0	0.01	0.02
Proceeds from Sale of Investments	-	-	-	-	-	1
Investing Cash Flow	-1.05	-1.21	-0.46	-1.89	-3.96	-1.6
Short-Term Debt Issued	-	-	-	2	-	-
Short-Term Debt Repaid	-	-	-	-2	-	-
Long-Term Debt Issued	-	0.8	-	3	2	0.4
Long-Term Debt Repaid	-2.3	-2.28	-1.47	-1.19	-0.9	-0.77
Net Long-Term Debt Issued (Repaid)	-2.3	-1.48	-1.47	1.81	1.1	-0.37
Issuance of Common Stock	0.33	0.35	4.65	0.02	0.03	4.24
Net Common Stock Issued (Repurchased)	0.33	0.35	4.65	0.02	0.03	4.24
Other Financing Activities	-0.04	-0.08	-0.3	-0.08	-0.02	0
Financing Cash Flow	-1.21	-1.21	2.88	1.75	1.11	3.88
Net Cash Flow	2.21	0.05	2.78	-4.81	-4.39	3.24
Free Cash Flow	3.38	1.22	-0.11	-6.57	-5.52	-1.65
Free Cash Flow Growth	175.62%	-	-	-	-	-
FCF Margin	11.28%	4.43%	-0.41%	-37.59%	-29.72%	-8.60%
Free Cash Flow Per Share	0.37	0.14	-0.01	-0.85	-0.71	-0.22
Levered Free Cash Flow	-2.54	-3.45	-0.22	-4.82	-5.65	-1.32
Unlevered Free Cash Flow	2.85	0.74	1.75	-6.61	-6.56	-0.58

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q